NCT03720002View on ClinicalTrials.gov

HF2 Therapy in the Treatment of Active Ulcerative Colitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Ulcerative Colitis
Interventions
DIETARY_SUPPLEMENT

HF2

placebo

Trial Locations (2)

52621

Sheba Medical Center, Ramat Gan

Unknown

Evaggelismos medical center, Athens

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV

NCT03720002 - HF2 Therapy in the Treatment of Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter